Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1Lymphoma 1Colonic Neoplasms 1

Interventions

Pemetrexed 15Cisplatin 13pembrolizumab 6Platinum 41,2-diaminocyclohexaneplatinum II citrate 4cediranib 3Radiotherapy 3Gemcitabine 3Carboplatin 3amatuximab 2Radiotherapy, Intensity-Modulated 2Radiation 2Everolimus 2Drug Therapy 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1sodium thiosulfate 1sargramostim 1nintedanib 1napabucasin 1methoxyamine 1liposomal doxorubicin 1incomplete Freund's adjuvant 1fresolimumab 1durvalumab 1defactinib 1cixutumumab 1bintrafusp alfa protein, human 1bemcentinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mesothelioma, Malignant × methoxyamine × Clear all
NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡